Axonics (AXNX)
(Real Time Quote from BATS)
$67.00 USD
-0.01 (-0.02%)
Updated May 30, 2024 01:02 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXNX 67.00 -0.01(-0.02%)
Will AXNX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXNX
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
AXNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
Other News for AXNX
Top Merger Stocks Held By Fund Managers, Mid-Q2 2024
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
Axonics receives regulatory approval for recharge-free SNM system in Australia
Baron Small Cap Fund Q1 2024 Shareholder Letter
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)